Corneal Perforation during Combination Chemotherapyincluding Cetuximab in a Patient with a History ofHerpetic Keratitis

o report a case of corneal perforation, in a patient with a history of herpetic keratitis, during combination chemotherapyincluding cetuximab.Case. We report the case of a 71-year-old man who was diagnosed with a hypopharyngeal carcinoma andreceived radiation therapy combined with cetuximab, the epidermal growth factor receptor (EGFR) inhibitor monoclonalantibody. He was referred to us because of ocular hyperemia and corneal perforation in his left eye. In spite of conservativetherapy, his corneal perforation was exacerbated, with iris incarceration into the wound site and exposure to the surface of thecornea. He therefore discontinued treatment with the combination chemotherapy and underwent lamellar keratoplasty using apreserved donor cornea. After treatment with cetuximab resumed, there was no recurrence of the corneal perforation.Conclusion. We have presented thefirst case of cetuximab-related corneal perforation in a patient who had a history ofrecurrent herpetic keratitis. EGFR inhibitors, such as cetuximab, can induce corneal perforation in cases with a history ofherpetic stromal keratitis